MX2020008771A - Agonistas del estimulador de genes interferon. - Google Patents

Agonistas del estimulador de genes interferon.

Info

Publication number
MX2020008771A
MX2020008771A MX2020008771A MX2020008771A MX2020008771A MX 2020008771 A MX2020008771 A MX 2020008771A MX 2020008771 A MX2020008771 A MX 2020008771A MX 2020008771 A MX2020008771 A MX 2020008771A MX 2020008771 A MX2020008771 A MX 2020008771A
Authority
MX
Mexico
Prior art keywords
sting
stimulator
interferon genes
compounds
agonists
Prior art date
Application number
MX2020008771A
Other languages
English (en)
Inventor
Luke L Lairson
Emily N Chin
Arnab Chatterjee
Manoj Kumar
Ana Maria Gamo Albero
Mike Petrassi
Peter Schultz
Chenguang Yu
Junko Tamiya
William Vernier
Anil Gupta
Ramkumar Modukuri
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of MX2020008771A publication Critical patent/MX2020008771A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Immunology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención proporciona compuestos que tienen bioactividad agonista del Estimulador de Genes de Interferón (STING) que se pueden usar en el tratamiento de tumores en pacientes afectados con ellos. Los compuestos de la fórmula (I): (Ver Fórmula I). Como se la define en la presente. Los compuestos para la práctica de un método de la invención se pueden administrar por vía oral para la exposición sistémica, así como por vía intratumoral. La antitumor mediante el uso de un compuesto de la fórmula (I) también puede comprender la administración de una dosis efectiva de un fármaco dirigido al control inmune.
MX2020008771A 2018-02-21 2019-02-21 Agonistas del estimulador de genes interferon. MX2020008771A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862633409P 2018-02-21 2018-02-21
PCT/US2019/018899 WO2019165032A1 (en) 2018-02-21 2019-02-21 Agonists of stimulator of interferon genes sting

Publications (1)

Publication Number Publication Date
MX2020008771A true MX2020008771A (es) 2020-11-13

Family

ID=67687383

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008771A MX2020008771A (es) 2018-02-21 2019-02-21 Agonistas del estimulador de genes interferon.

Country Status (10)

Country Link
US (1) US11701364B2 (es)
EP (1) EP3755331A4 (es)
JP (2) JP7104999B2 (es)
KR (1) KR20200123179A (es)
CN (2) CN117942342A (es)
AU (1) AU2019225919B2 (es)
CA (1) CA3091670C (es)
IL (1) IL276844B1 (es)
MX (1) MX2020008771A (es)
WO (1) WO2019165032A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11638716B2 (en) 2017-08-31 2023-05-02 F-star Therapeutics, Inc. Compounds, compositions, and methods for the treatment of disease
EP3755331A4 (en) 2018-02-21 2021-11-17 The Scripps Research Institute AGONISTS OF THE STIMULATOR OF INTERFERON GENES (STING)
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
CN113811300A (zh) * 2019-03-15 2021-12-17 总医院公司 Tead转录因子的新型小分子抑制剂
JP7485399B2 (ja) * 2019-08-21 2024-05-16 ザ スクリプス リサーチ インスティテュート インターフェロン遺伝子の刺激因子ｓｔｉｎｇの単環式アゴニスト
EP4017593A1 (en) * 2019-08-21 2022-06-29 The Scripps Research Institute Bicyclic agonists of stimulator of interferon genes sting
KR20220100607A (ko) * 2019-10-28 2022-07-15 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 5원 헤테로사이클릭 옥소카르복실산 화합물 및 이의 의약 용도
US20230141284A1 (en) 2020-04-10 2023-05-11 Ono Pharmaceutical Co., Ltd. Cancer therapeutic method
US20210380695A1 (en) 2020-05-15 2021-12-09 Immunesensor Therapeutics, Inc. Sting agonist combination treatments with immune checkpoint inhibitors
AU2021338438A1 (en) * 2020-09-02 2023-03-23 The Scripps Research Institute Agonists of stimulator of interferon genes sting
US11964978B2 (en) 2021-03-18 2024-04-23 Pfizer Inc. Modulators of STING (stimulator of interferon genes)
CN117836007A (zh) * 2021-07-13 2024-04-05 南京大学 一种pt偶联物及其用途
WO2023004440A2 (en) 2021-07-23 2023-01-26 Immunesensor Therapeutics, Inc. Sting agonist combination treatments with cytokines
CN116239574A (zh) * 2021-12-07 2023-06-09 中国科学院上海药物研究所 Sting小分子激动剂、其制备方法及应用
GB202304385D0 (en) 2023-03-24 2023-05-10 Prostate Cancer Res Combinatorial IL-15 therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011048525A1 (en) 2009-10-20 2011-04-28 Pfizer Inc. Novel heteroaryl imidazoles and heteroaryl triazoles as gamma-secretase modulators
CN103204813A (zh) * 2012-01-12 2013-07-17 格兰马克药品股份有限公司 作为trpv3拮抗剂的稠合咪唑衍生物
MX2016015928A (es) 2014-06-04 2017-03-20 Glaxosmithkline Ip Dev Ltd Dinucleotidos ciclicos como moduladores de sting.
US10738074B2 (en) * 2015-08-13 2020-08-11 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as STING agonists
EP3366691A1 (en) * 2015-12-03 2018-08-29 GlaxoSmithKline Intellectual Property Development Limited Cyclic purine dinucleotides as modulators of sting
EP3755331A4 (en) 2018-02-21 2021-11-17 The Scripps Research Institute AGONISTS OF THE STIMULATOR OF INTERFERON GENES (STING)

Also Published As

Publication number Publication date
JP7104999B2 (ja) 2022-07-22
JP2022130684A (ja) 2022-09-06
JP2021514375A (ja) 2021-06-10
RU2020130864A (ru) 2022-03-23
AU2019225919B2 (en) 2022-04-21
JP7366456B2 (ja) 2023-10-23
KR20200123179A (ko) 2020-10-28
EP3755331A1 (en) 2020-12-30
US11701364B2 (en) 2023-07-18
AU2019225919A1 (en) 2020-09-24
WO2019165032A1 (en) 2019-08-29
IL276844B1 (en) 2024-09-01
CA3091670A1 (en) 2019-08-29
CN117942342A (zh) 2024-04-30
IL276844A (en) 2020-10-29
CN111971045A (zh) 2020-11-20
US20210205321A1 (en) 2021-07-08
CA3091670C (en) 2023-02-28
CN111971045B (zh) 2024-05-03
EP3755331A4 (en) 2021-11-17

Similar Documents

Publication Publication Date Title
MX2020008771A (es) Agonistas del estimulador de genes interferon.
MX2007009960A (es) Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion.
EA201650134A1 (ru) Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором
HK1104968A1 (en) Use of immunomodulatory compounds in the manufacture of a medicament for the treatment and management of cancers and other diseases, and compositions thereof
MXPA05012155A (es) Metodos y composiciones que utilizan compuestos inmunomoduladores para el tratamiento y manejo de canceres y otras enfermedades.
ZA202203202B (en) Monocyclic agonists of stimulator of interferon genes sting
MX2009007597A (es) Terapia especifica y medicamento que utilizan ligandos de integrina para tratar el cancer.
NZ775836A (en) Methods for shrinking pituitary tumors
MX2022000430A (es) Administracion de agonista de sting e inhibidores de puntos de control.
PH12020551018A1 (en) Oral delivery of glp-1 peptide analogs
PH12020551715A1 (en) Methods of treating cancer
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
MX2022011372A (es) Composiciones de zinc-y-pga y metodos para tratar el cancer.
PH12020500665A1 (en) Pladienolide derivatives as spliceosome targeting agents for treating cancer
MX2019010338A (es) Administracion concomitante de moduladores de receptores de glucocorticoides e inhibidores de cyp3a.
MX2017016183A (es) Vacuna de adn que dirige vegfr-2 para terapia de combinacion.
MX2023005295A (es) Tratamiento contra el cancer resistente a platino.
EA202192757A1 (ru) Способ лечения опухолей
ZA202203203B (en) Bicyclic agonists of stimulator of interferon genes sting
PH12020500096A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor
WO2022046452A3 (en) Nanoparticulate system for delivery of pain relief agents
MX2023011203A (es) Derivado de cumarina para terapia o profilaxis de un trastorno proliferativo celular.
MY197664A (en) Immunity enhancing agent for cancer by allergin-1 antagonist
WO2022174064A3 (en) Therapeutic composition and method combining multiplex immunotherapy with cancer vaccine for the treatment of cancer
WO2018211336A3 (en) Solid dosage form containing sorafenib tosylate